Clinical Trial Update: Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) [Phase 1, Phase 2]

View source ↗

Summary

Genmab is conducting a Phase 1/2 clinical trial of Rinatabart Sesutecan for multiple advanced solid tumors; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• High-grade Epithelial Ovarian Cancer
• High-grade Serous Ovarian Cancer
• Mesothelioma
• Non-small Cell Lung Cancer
• Platinum-resistant Ovarian Cancer
• Platinum-sensitive Ovarian Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Rinatabart Sesutecan (Rinatabart Sesutecan)

Snippet

Sponsor: Genmab | Conditions: High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer | Phase 1, Phase 2 | Status: RECRUITING